Ascletis Pharma, Inc. (HK:1672)
:1672
Want to see HK:1672 full AI Analyst Report?
1672 Stock Chart & Stats
HK$18.48
HK$0.09(3.03%)
At close: 4:00 PM EST
HK$18.48
HK$0.09(3.03%)
Day’s Range― - ―
52-Week RangeHK$6.20 - HK$19.86
Previous CloseN/A
Volume2.91M
Average Volume (3M)8.30M
Market Cap
HK$15.76B
Enterprise ValueHK$12.17B
Total Cash (Recent Filing)HK$1.90B
Total Debt (Recent Filing)HK$5.16M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 24, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding1,068,455,100
10 Day Avg. Volume6,104,199
30 Day Avg. Volume8,303,348
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)5.14
Price to Sales (P/S)4905.97
P/FCF Ratio-30.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$20.17Price Target Upside9.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.9
Revenue Forecast (FY)HK$1.29B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity provides a durable solvency buffer for a biotech with long development cycles. This reduces near-term refinancing risk, preserves optionality to fund trials or partnerships, and gives time to execute strategic remedies if cash burn persists.
Diversified Commercial And Collaboration Revenue ModelA mix of marketed-product sales plus licensing, milestone and royalty potential diversifies revenue levers beyond a single asset. That business model lowers binary clinical risk, supports multiple monetization paths, and can sustain funding via partner payments even during internal commercialization gaps.
Integrated R&D-to-commercial Capabilities And Antiviral FocusIn-house R&D, manufacturing and commercialization capabilities create durable vertical integration advantages: faster internal coordination, capture of downstream margins, and potential for repeatable product rollouts in the antiviral area, which remains a structurally relevant therapeutic market.
Bears Say
Severe Revenue CollapseThe dramatic multi-year revenue decline materially erodes the business base and impairs the company’s ability to cover fixed costs. Without a sustained top-line recovery, product commercialization economics and long-term viability hinge on new launches or sizeable partner financings.
Sustained Negative Cash Flow And Accelerating BurnConsistent operating and free cash outflows, with burn stepping up recently, deplete reserves and force dependence on external financing or asset monetization. This constrains R&D and commercialization investment and increases dilution or restructuring risk if trends persist.
Deep Losses And Negative Gross ProfitNegative gross profit signals that direct costs exceed revenue, indicating the cost base is fundamentally misaligned with current sales. That undermines margin sustainability, erodes equity returns, and necessitates structural cost reduction or significant revenue recovery to restore profitability.
Ascletis Pharma, Inc. News
1672 FAQ
What was Ascletis Pharma, Inc.’s price range in the past 12 months?
Ascletis Pharma, Inc. lowest stock price was HK$6.20 and its highest was HK$19.86 in the past 12 months.
What is Ascletis Pharma, Inc.’s market cap?
Ascletis Pharma, Inc.’s market cap is HK$15.76B.
When is Ascletis Pharma, Inc.’s upcoming earnings report date?
Ascletis Pharma, Inc.’s upcoming earnings report date is Aug 24, 2026 which is in 95 days.
How were Ascletis Pharma, Inc.’s earnings last quarter?
Ascletis Pharma, Inc. released its earnings results on Mar 31, 2026. The company reported -HK$0.321 earnings per share for the quarter, the consensus estimate of -HK$0.321 by HK$0.
Is Ascletis Pharma, Inc. overvalued?
According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Undervalued.
Does Ascletis Pharma, Inc. pay dividends?
Ascletis Pharma, Inc. does not currently pay dividends.
What is Ascletis Pharma, Inc.’s EPS estimate?
Ascletis Pharma, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Ascletis Pharma, Inc. have?
Ascletis Pharma, Inc. has 1,068,455,100 shares outstanding.
What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?
Ascletis Pharma, Inc. reported an EPS of -HK$0.321 in its last earnings report, expectations of -HK$0.321. Following the earnings report the stock price went down -1.129%.
Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:1672
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascletis Pharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
612.66%
12-Months-Change
Fundamentals
Return on Equity
-18.69%
Trailing 12-Months
Asset Growth
1.80%
Trailing 12-Months
Company Description
Ascletis Pharma, Inc.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
1672 Stock 12 Month Forecast
Average Price Target
HK$20.17
▲(9.15% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---